Oncology Examination: Difference between revisions

m (Text replacement - "''' ==" to "")
mNo edit summary
Line 9: Line 9:
<br>  
<br>  


= '''Using the International Classification Framework Model for Assessment in Oncology Rehabilitation by Gilchrist LS, Galantino ML, Wampler M, et al.<ref name="Oncology Framework">Gilchrist LS, Galantino ML, Wampler M, et al. A framework for assessment in oncology rehabilitation. Phys Ther. 2009;89:286–306.</ref>&nbsp;&nbsp;[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967778/ Link to reference]''' =
== '''Using the International Classification Framework Model for Assessment in Oncology Rehabilitation by Gilchrist LS, Galantino ML, Wampler M, et al.<ref name="Oncology Framework">Gilchrist LS, Galantino ML, Wampler M, et al. A framework for assessment in oncology rehabilitation. Phys Ther. 2009;89:286–306.</ref>&nbsp;&nbsp;[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967778/ Link to reference]''' ==


==<span style="font-size: 18px; font-weight: bold; line-height: 1.5em;">I. &nbsp;Mental Function, Pain &amp; Somatorsensory Screening</span>
==Mental Function, Pain &amp; Somatorsensory Screening==


Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system<ref name="Breast Cancer Cognitive Dysfunction">Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.</ref>&nbsp;<ref>Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.</ref><ref>Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.</ref>&nbsp;Mental impairments can be indusced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage<ref>Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493</ref>. &nbsp;Emotional Functions may alos affect the ability of our patients to respond to and/or participate in physical therapy.  
Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system<ref name="Breast Cancer Cognitive Dysfunction">Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.</ref>&nbsp;<ref>Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.</ref><ref>Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.</ref>&nbsp;Mental impairments can be indusced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage<ref>Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493</ref>. &nbsp;Emotional Functions may alos affect the ability of our patients to respond to and/or participate in physical therapy.  
Line 41: Line 41:
=== 3. &nbsp;Neurological Assessment Measure  ===
=== 3. &nbsp;Neurological Assessment Measure  ===


==== a) '''&nbsp;Vestibular==
==== a) '''&nbsp;Vestibular====


May be affected by neoplasms such as a&nbsp;<span style="line-height: 1.5em;">Vestibular schwannoma which may cause unilateral dysfunction&nbsp;</span><span style="line-height: 1.5em;">or chemotherapy &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; drugs such as&nbsp;</span>Cisplastin  
May be affected by neoplasms such as a&nbsp;<span style="line-height: 1.5em;">Vestibular schwannoma which may cause unilateral dysfunction&nbsp;</span><span style="line-height: 1.5em;">or chemotherapy &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; drugs such as&nbsp;</span>Cisplastin  
Line 65: Line 65:
== II. Neuromusculoskeletal Function (Movement Related Functional Assessment)  ==
== II. Neuromusculoskeletal Function (Movement Related Functional Assessment)  ==


===Posture=
===Posture==


===ROM=
===ROM==


*Scar tissue formation after surgical resections, chemotherapy or radiation therapy. &nbsp;  
*Scar tissue formation after surgical resections, chemotherapy or radiation therapy. &nbsp;  
*Fibrosis after irradiation.
*Fibrosis after irradiation.


===Strength=
===Strength==


*Muscle weaknesses from inflammatory intermediates produced by the tumor that are catabolic and cause muscle wasting (cachexia).  
*Muscle weaknesses from inflammatory intermediates produced by the tumor that are catabolic and cause muscle wasting (cachexia).  
Line 80: Line 80:
*MMT
*MMT


===Balance=
===Balance==


Balance Dysfunction can be caused from any of the following  
Balance Dysfunction can be caused from any of the following  
Line 101: Line 101:
*Timed Get up &amp; Go Test
*Timed Get up &amp; Go Test


===Gait=
===Gait==


*Kinetmatic Analysis  
*Kinetmatic Analysis  
Line 112: Line 112:
== III. &nbsp;System Screening  ==
== III. &nbsp;System Screening  ==


===Cardiovascular=
===Cardiovascular==


*Cardiotoxicity can be a late effect of chemotherapy due damage o fthe cardiac myoctyes ultimately resulting in congestive heart failure.  
*Cardiotoxicity can be a late effect of chemotherapy due damage o fthe cardiac myoctyes ultimately resulting in congestive heart failure.  
Line 121: Line 121:
#Echocardiogram to assess ventricular function, cardiac motion and output.
#Echocardiogram to assess ventricular function, cardiac motion and output.


===Hematologic=
===Hematologic==


===Immunologic=
===Immunologic==


*Damage to lymph vessels by tumor obstruction, surgical resection of lymph nodes, radiation leading to fibrosis of the lymph vessels
*Damage to lymph vessels by tumor obstruction, surgical resection of lymph nodes, radiation leading to fibrosis of the lymph vessels
Line 132: Line 132:
#Water Displacement Method of measuring limb volume
#Water Displacement Method of measuring limb volume


===Integumentary=
===Integumentary==


*With lymphedema, skin breakdown or infection can occur. &nbsp;  
*With lymphedema, skin breakdown or infection can occur. &nbsp;  
Line 191: Line 191:
== V. &nbsp;Functional Activities, Mobility &amp; Self-Care  ==
== V. &nbsp;Functional Activities, Mobility &amp; Self-Care  ==


===Measures=
===Measures==


*Functional Mobility Assessment
*Functional Mobility Assessment
Line 242: Line 242:
&nbsp; &nbsp; &nbsp;Measures adults' perception o ftheir ability to resume life roles after trauma or illness  
&nbsp; &nbsp; &nbsp;Measures adults' perception o ftheir ability to resume life roles after trauma or illness  


== Recent Related Research (from [http://www.ncbi.nlm.nih.gov/pubmed/ Pubmed])  ==
<div class="researchbox">
<rss>Feed goes here!!</rss>
</div>
== References  ==
== References  ==
References will automatically be added here, see [[Adding References|adding references tutorial]].


<references />  
<references />  


[[Category:Oncology]]
[[Category:Oncology]]

Revision as of 03:05, 20 July 2019




Using the International Classification Framework Model for Assessment in Oncology Rehabilitation by Gilchrist LS, Galantino ML, Wampler M, et al.[1]  Link to reference[edit | edit source]

Mental Function, Pain & Somatorsensory Screening[edit | edit source]

Mental function can be affected by radiation and chemotherapy through the changes in the central nervous system[2] [3][4] Mental impairments can be indusced by inflammation, destructive autoimmune responses, toxicity levels and oxidative damage[5].  Emotional Functions may alos affect the ability of our patients to respond to and/or participate in physical therapy.

Diagnostic & Screening Measures[edit | edit source]

1.  Mental Status[edit | edit source]

              The Mini-Mental State Examination[6] 

                   read more about the Mini-Mental State Examination Measure & Link

              Profile of Mood States[7]

                   read more about the POMS

2.  Pain Assessment[edit | edit source]

                     1.  Visual Analog Scale

                     2.  Numeric Rating Scale

                     3.  Faces Pain Scale

                     4.  Brief Pain Inventory[8]

                     

3.  Neurological Assessment Measure[edit | edit source]

a)  Vestibular[edit | edit source]

May be affected by neoplasms such as a Vestibular schwannoma which may cause unilateral dysfunction or chemotherapy                             drugs such as Cisplastin

Dizziness Handicap Inventory Questionnaire--25 items assess the impact of disequilibrium on functional activities.[9]

b)  Somatosensory[edit | edit source]

c)  Neuromusculoskeletal[edit | edit source]

1.  Peripheral Neuropathies--Chemotherapy induced

          modified Total Neuropathy Score[10]

2.  Anesthesia/Dysesthesias

         with compression or surgical dissection of nerves

3.  Motor Function Loss

         Radiation Plexopathy

II. Neuromusculoskeletal Function (Movement Related Functional Assessment)[edit | edit source]

=Posture[edit | edit source]

=ROM[edit | edit source]

  • Scar tissue formation after surgical resections, chemotherapy or radiation therapy.  
  • Fibrosis after irradiation.

=Strength[edit | edit source]

  • Muscle weaknesses from inflammatory intermediates produced by the tumor that are catabolic and cause muscle wasting (cachexia).
  • Surgical denervation or damage
  • Radiation & Chemotherapy can damage muscle or nerve tissue.  (Vinca alkaloids, taxanes and platinum agents)
  • Grip dynamometers
  • MMT

=Balance[edit | edit source]

Balance Dysfunction can be caused from any of the following

  • sensory input
  • central processing of balance-related information
  • ROM limitations
  • orthostatic hypotension
  • muscle weakness
  • peripheral neuropathies from taxane


Balance Measures

  • Functional Reach
  • Berg Balance Scale
  • Standard Romberg Test
  • Tandem Romberg Test
  • Timed Get up & Go Test

=Gait[edit | edit source]

  • Kinetmatic Analysis
  • Gait Speed Measurements

Gait Measures

  • Tinetti Balance & Gait Scale

III.  System Screening[edit | edit source]

=Cardiovascular[edit | edit source]

  • Cardiotoxicity can be a late effect of chemotherapy due damage o fthe cardiac myoctyes ultimately resulting in congestive heart failure.
  • Radiation may scar the cardiac and coronary arteries resulting in restrictive coronary disease

Measures

  1. Echocardiogram to assess ventricular function, cardiac motion and output.

=Hematologic[edit | edit source]

=Immunologic[edit | edit source]

  • Damage to lymph vessels by tumor obstruction, surgical resection of lymph nodes, radiation leading to fibrosis of the lymph vessels

Measures

  1. Limb Circumfrence Measurements Pre-op and Post-op
  2. Water Displacement Method of measuring limb volume

=Integumentary[edit | edit source]

       Uses Grades to assess severity of different conditions for example Lymphedema

==Respiratory[edit | edit source]

  • Lung tumors may limit thoracic cavity expansion, compress the airways or reduce the surface area of the lung.  
  • Chemotherapy agents (beomycin, methotrexate and docetaxel may damage pneumocytes.  This reduces alveoli and air exchange.
  • Patients are then at risk for pneumonitis or fibrosis.

Measures[edit | edit source]

  1. Vital signs (RR, HR, BP)
  2. Oxygen Sautration
  3.  Aerobic Test--6 Minute Walk
  4. Dyspnea Scale
  5. Borg Rating of Perceived Exertion


IV.  Red and Yellow Flag Measures & Risk Patterns[edit | edit source]

Sites at Risk for Neural Compression

Brachial Plexus:  Breast & Lung Tumors

Lumbosacral Plexus:  Colorectal & Gynecological Tumors, Sarcomas & Lymphomas

Symptoms:  Unrelenting pain, worse at night progressing to focal sensory loss or weakness

Cancers that often metastasize to the Spine

  • Prostate
  • Breast
  • Lung 
  • Colon

Cancers that often present in the femur

  • Sarcoma

Cancer and Cancer Treatment increases risk for Osteonecrosis

  • Proximal or Distal Femur
  • Proximal Humerus
  • Jaw
  • Metatarsals

Other Risks

  • Osteoporosis
  • Neutropenia
  • Thrombocytopenia

V.  Functional Activities, Mobility & Self-Care[edit | edit source]

=Measures[edit | edit source]

  • Functional Mobility Assessment

     requires patients to physically perform specific tasks and to answer questions, quantifying their level of function.

  • The Toronto Extremity Salvage Score, lower-extremity version

     is a self administered questionnaire that asks patients to indicate the level of difficulty they experience in dressing,grooming, mobility, work, sports, and leisure


Mobility Assessment

  • changing and maintaining body positions
  • carrying
  • moving and handling objects
  • walking
  • moving around using transportation


Self Care Measures

includes grooming, bathing and dressing

  • Karnofsky Performance Scale

      A standard measure of the ability of adult patients with cancer to perform ordinary tasks. scores range from 0 to 100. A higher score               means the patient is better able to carry out daily activities

  • Barthel Index  includes multiple components and diverse self-care activities. May be more responsive in rehabilitation.
      Performance or self-report measure of independence in basic activities of daily living


Shoulder Measures for Breast Cancer[11]

  • The Functional Assessment of Cancer Therapy Breast (FACT-B+4)
  • Disability of Arm, Shoulder and Hand (DASH) questionnaires.

VI.  Psychosocial[edit | edit source]

Consider the patients domestic life, interpersonal relations and major life areas.  

assess participation in or attending community activities, reduced job expectations etc

Measures

  • Reintegration to Normal Living Index

     Measures adults' perception o ftheir ability to resume life roles after trauma or illness

References[edit | edit source]

  1. Gilchrist LS, Galantino ML, Wampler M, et al. A framework for assessment in oncology rehabilitation. Phys Ther. 2009;89:286–306.
  2. Ahles T, Saykin A. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer.2002;3:S84–S90.
  3. Castellon S, Ganz P, Bower J, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–969.
  4. Stewart A, Bielajew C, Collins B, et al. A meta analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.
  5. Ahles T, Saykin A, Furstenberg C, et al. Neuropsychologic impact of standard dose systemic chemotherapy in longterm survivors of breast cancer and lymphoma.J Clin Oncol. 2002;20:485–493
  6. Folstein M, Folstein S, McHugh P. Mini-Mental State: a practical method for grading the state of patients for the clinician J Psychiatr Res. 1975;12:189–198.
  7. Cella D, Tross S, Orov E, et al. Mood states of patients after the diagnosis of cancer. J Psychosoc Oncol. 1989;7:45–53.
  8. Cleeland C. Measurement and prevalence of pain in cancer. Semin Oncol Nurs. 1985;1:87–92.
  9. Jacobson G, Newman C, Hunter L, Balzer G. Balance function test correlates of the Dizziness Handicap Inventory. J Am Acad Audiol. 1991;2:253–260.
  10. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003;61:fckLR1297–1300.
  11. Davies C, Ryans K, Levenhagen K, Perdomo M. Quality of Life and Functional Outcome Measures for Secondary Lymphedema in Breast Cancer Survivors. Rehabil Oncol Vol 32 (1)p. 7-12